Servier

Welcome to our page. Servier is committed to therapeutic progress to serve patient needs. Neurology will constitute a future growth driver.

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide.

----

To report a suspected adverse event with a Servier drug 👉 https://bit.ly/435zpoI

12/01/2026

🔬As we saw in the first episode, identifying a promising molecule is only the first step. Before a medicine can be given to patients, we must ensure that it is safe and effective. That’s where preclinical research comes in.

🧫 In this stage, scientists study how the molecule behaves in controlled environments. Through in vitro and in vivo testing, scientists assess the molecule's safety, toxicity, and pharmacological properties, to determine if it is ready for human trials.

🔍 After several years of rigorous testing, the results are compiled, and the discovery is patented to protect the innovation as it moves toward the next big step: clinical research in humans.

Discover more in our next videos 💡

10/01/2026

💡 What if tomorrow’s medicines were already taking shape… in a lab dish?

🧫 At Servier, our In Vitro Pharmacology (IVP) teams recreate human biology to understand diseases and test new drug candidates long before clinical trials begin. Using AI, robotics, and patient-derived models, they help shape the future of treatments in oncology, neurology, and immunology.

These passionate researchers are turning scientific curiosity into therapeutic progress.

Learn more about their team in Sundari Journal No. 3 👉 https://bit.ly/4phpRSA

09/01/2026

🎥 Meet Ana Raquel & Marius: Two passionate postdoctoral researchers at Servier, each driven by the desire to make a difference in patients’ lives.

Ana Raquel, a Brazilian neuroscientist, is focused on investigating subtypes of epilepsy diagnosed in children—hoping to contribute to a brighter future for young patients. Marius, a specialist in vivo pharmacology, is working to better understand neurodegenerative diseases like spinal cerebellar ataxia type 3.

Their journeys illustrate how science is shaped by curiosity, perseverance, and the willingness to explore new ideas. At Servier, we value and support researchers who are dedicated to advancing knowledge and making a positive impact for patients.

✨ Watch their inspiring stories!

08/01/2026

🔬 Creating new medicines is hard because many molecules don’t have the right shape to work on complex diseases.

🧫 At Servier, PhD researcher Emilie Gentilini and her team are using a technique called gold catalysis to build more advanced molecules. These molecules are inspired by nature and have 3D structures that could make treatments more effective.

Her work helps expand Servier’s collection of molecules, increasing the chances of finding new options for diseases that are difficult to treat.

Learn more below and in Sundari Journal No. 3 👉 https://bit.ly/4phpRSA

07/01/2026

💬 “Every day, I have to ensure the development of new data tools that will drive the therapeutic projects, and that will impact them in terms of the probability of success. We want to shorter the time to deliver high quality drug for the patient.”

Meet Alban Arrault, R&D Chief A.I. Officer, who is leading innovation by combining AI, data, and human collaboration to accelerate the development of new medicines. 💊⚙️

🤝 With over 17 years at Servier, Alban’s journey from chemist to Chief A.I. Officer illustrates how technology and teamwork can transform drug discovery and deliver better treatments to patients worldwide.

Learn more about our digital transformation commitments and AI usage at https://bit.ly/44Pb6iE

06/01/2026

💬 “Even if I’m a small piece of this whole drug discovery process, I’m very motivated to know that artificial intelligence can help and can accelerate drug discovery for the patient.”

Meet Alban Arrault, R&D Chief A.I. Officer. He’s driving innovation by combining AI, data, and human collaboration to speed up the development of new medicines. 💊⚙️

🤝 With over 17 years at Servier, Alban shares how his journey from chemist to Chief A.I. Officer reflects a shared purpose: using technology and teamwork to deliver better treatments faster for patients worldwide.

Learn more about our digital transformation commitments and AI usage at https://bit.ly/44Pb6iE

05/01/2026

👨‍🔬 The story of a medicine begins long before it reaches patients, in the lab, where researchers search for solutions to unmet medical needs.

💊 In this first episode of our series on the life cycle of a medicine, we explore how researchers transform a need into a potential treatment.

🔍 From understanding diseases and identifying biological targets to screening thousands of compounds, innovation takes root in this early stage of drug discovery. This long and meticulous process often takes three to five years before a promising molecule is selected as a drug candidate.

Watch the video below to learn more and stay tuned to find out what's next. 💭

04/01/2026

🔍 What if subtle behaviors could reveal the secrets of a rare neurological disease?

🧠 Spinocerebellar Ataxia Type 3 (SCA3) is a rare inherited disorder that gradually affects movement, balance, and coordination.

🐁 At Servier, postdoctoral researcher Marius Halliez is studying this disease using a system that tracks behavior continuously in a natural environment.

By observing subtle changes, researchers gain a clearer picture of disease progression, eventually helping to develop and test future treatments.

📖 Learn more below and in Sundari Journal No. 3 👉 https://bit.ly/4phpRSA

03/01/2026

🧪 Imagine creating dozens of potential medicines in one experiment.

🔎 At Servier, the Drug Design Small Molecules (DDSM) unit, where Raphael Steimbach works, uses High-Throughput Experimentation (HTE) to accelerate drug discovery.

🔬 By miniaturizing reactions and automating workflows, researchers can test hundreds of conditions and build diverse chemical libraries

Learn more about HTE and their research below and in Sundari Journal No. 3 👉 https://bit.ly/4phpRSA

02/01/2026

80+ young researchers, one shared ambition: innovate. Discover their latest insights in the 3rd edition of SUNDARI, created by the SHINEDocs community! 🚀

🧠 The SHINEDocs program brings together doctoral and postdoctoral students from our R&D teams and partner laboratories in France and around the world. These students represent the next generation of scientific innovation.

🎤 Through specialized training, career guidance, and networking activities, the program enables these young researchers to develop their skills and collaborate with one another. United by their passion for innovation, our SHINEDocs participants truly represent the next generation of medical research.

Discover their latest insights in Sundari Journal No. 3. 👉 https://bit.ly/4phpRSA

01/01/2026

🎉 Happy New Year 2026!
We wish you a wonderful, inspiring, and impactful year 2026! ✨

As we welcome 2026, our thoughts go first to the people who give meaning to everything we do: the patients, and all those who stand beside them — caregivers, partners, and our incredible teams around the world. 🌍

Thank you for inspiring us every single day. 🙏
This new year is an opportunity to reaffirm what defines us as a Group and what drives our commitment to therapeutic progress to serve patient needs.

Learn more about Servier 🔗 https://servier.com/en/

31/12/2025

🎉 In this special day, we wish you a Happy New Year!

As 2025 comes to an end, we want to thank all of you for being part of our journey.

Together, we achieved incredible milestones for patients worldwide, and this is just the beginning.

✨ May 2026 be a year filled with joy, health, and happiness in every way for you, our patients, families, colleagues, partners, and followers.

Adresse

50, Rue Carnot
Suresnes
92150

Téléphone

+33 1 55 72 60 00

Site Web

https://servier.com/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Servier publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.

Raccourcis

Vous voulez que votre pratique soit Clinique la plus cotée à Suresnes ?

Type

Centre de recherche médicale

Our Story

Servier is an international pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France.

With a strong international presence in 149 countries and a turnover of € 4.2 billion in 2018, Servier employs 22.000 people worldwide.

Entirely independent, Servier reinvests 25% of its revenue (excluding generic drugs) in research and development and uses all its profits for development.